Rafik Fellague-Chebra

Dr. Rafik Fellague-Chebra is a globally recognized oncology leader with over 20 years of experience spanning clinical practice, research, and pharmaceutical development. With a background in medicine and biostatistics, he has driven innovation throughout his distinguished career. As Executive Global Group Medical Director at Novartis Oncology, Dr. Fellague-Chebra spearheads breakthrough initiatives in hematological and gastrointestinal malignancies. His previous leadership roles include key positions at Pfizer, where he led the successful launch of Sutent for renal cancer and neuroendocrine tumors, and at GSK, where he pioneered cancer vaccine development programs in gastro-intestinal and genito-urinary malignancies. Dr. Fellague-Chebra's current research focuses on the intersection of cancer biology and the human microbiome, a frontier he believes represents the next paradigm shift in precision oncology. His work explores how oncobiome modulation can overcome treatment resistance and enhance therapeutic efficacy. Beyond his professional achievements, Dr. Fellague-Chebra is dedicated to his family and maintains a balanced lifestyle through sports and nutrition, values that reinforce his commitment to improving cancer outcomes for patients worldwide.